…
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Danaher Corporation is a diversified science and technology company providing instruments, consumables and software for life sciences, diagnostics and environmental markets. Long-term growth may be supported by recurring consumables and service revenue, installed-base replacement cycles, geographic expansion and disciplined acquisitions executed via the Danaher Business System, and investors may find the company attractive for its diversified portfolio, strong market positions and stable cash generation.
Material risks include regulatory and reimbursement changes, competitive pressure and execution risk from acquisitions and new-product development, plus sensitivity to capital spending and supply-chain disruptions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8292.00M | 7598.00M | 4495.00M | 3305.30M | 3292.80M |
| Minority interest | - | - | 11.00M | 11.30M | 12.30M |
| Net income | 7209.00M | 6433.00M | 3646.00M | 3008.20M | 2650.90M |
| Selling general administrative | 8516.00M | 8198.00M | 6896.00M | 5588.30M | 6472.10M |
| Gross profit | 18949.00M | 17952.00M | 12475.00M | 9983.70M | 11107.10M |
| Reconciled depreciation | 2222.00M | 2168.00M | 1775.00M | 1189.50M | 1307.70M |
| Ebit | 8688.00M | 7465.00M | 4231.00M | 3269.40M | 3450.20M |
| Ebitda | 10725.00M | 10100.00M | 6116.00M | 4609.90M | 4757.90M |
| Depreciation and amortization | 2037.00M | 2635.00M | 1885.00M | 1340.50M | 1307.70M |
| Non operating income net other | -185.00M | 371.00M | 539.00M | 144.50M | 46.40M |
| Operating income | 8688.00M | 7465.00M | 4231.00M | 3269.40M | 3403.80M |
| Other operating expenses | 22783.00M | 21988.00M | 18053.00M | 14641.70M | 16489.20M |
| Interest expense | 211.00M | 238.00M | 275.00M | 108.60M | 157.40M |
| Tax provision | 1083.00M | 1251.00M | 849.00M | 873.00M | 641.90M |
| Interest income | 170.00M | 227.00M | 204.00M | 139.00M | 9.20M |
| Net interest income | -170.00M | -227.00M | -204.00M | 30.40M | -148.20M |
| Extraordinary items | 0.00M | 86.00M | 0.00M | 575.90M | 251.60M |
| Income tax expense | 1083.00M | 1251.00M | 849.00M | 873.00M | 641.90M |
| Total revenue | 31471.00M | 29453.00M | 22284.00M | 17911.10M | 19893.00M |
| Total operating expenses | 10261.00M | 10487.00M | 8244.00M | 6714.30M | 7703.30M |
| Cost of revenue | 12522.00M | 11501.00M | 9809.00M | 7927.40M | 8785.90M |
| Total other income expense net | -396.00M | 133.00M | 264.00M | 35.90M | 37.20M |
| Discontinued operations | - | 86.00M | 86.00M | 575.90M | 244.60M |
| Net income from continuing ops | 7209.00M | 6347.00M | 3646.00M | 2432.30M | 2650.90M |
| Net income applicable to common shares | 7103.00M | 6269.00M | 3510.00M | 2939.80M | 2650.90M |
| Preferred stock and other adjustments | 106.00M | 164.00M | 136.00M | 68.40M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 84350.00M | 83184.00M | 76161.00M | 62081.60M | 47832.50M |
| Intangible assets | 20300.00M | 22843.00M | 21282.00M | 9749.70M | 11673.10M |
| Other current assets | 1860.00M | 1664.00M | 1430.00M | 864.60M | 906.30M |
| Total liab | 34260.00M | 38007.00M | 36384.00M | 31799.70M | 19605.80M |
| Total stockholder equity | 50082.00M | 45167.00M | 39766.00M | 30270.60M | 28214.40M |
| Other current liab | 3854.00M | 3950.00M | 4130.00M | 2517.50M | 2391.70M |
| Common stock | 9.00M | 9.00M | 9.00M | 8.40M | 8.20M |
| Capital stock | 1677.00M | 3277.00M | 3277.00M | 1608.00M | 8.20M |
| Retained earnings | 39205.00M | 32827.00M | 27159.00M | 24166.30M | 25163.00M |
| Other liab | 5922.00M | 7699.00M | 7789.00M | 4711.80M | 5075.80M |
| Good will | 39752.00M | 41184.00M | 35420.00M | 22712.50M | 25906.00M |
| Other assets | 4459.00M | 3719.00M | 2395.00M | 923.40M | 5587.50M |
| Cash | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 787.80M |
| Cash and equivalents | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 787.80M |
| Total current liabilities | 8389.00M | 8140.00M | 7402.00M | 4932.10M | 4841.50M |
| Current deferred revenue | 1648.00M | 1613.00M | 1212.00M | 687.80M | 685.20M |
| Net debt | 13682.00M | 19590.00M | 15169.00M | 1816.80M | 8952.50M |
| Short term debt | 591.00M | 8.00M | 11.00M | 212.40M | 51.80M |
| Short long term debt | 591.00M | 8.00M | 11.00M | 212.40M | 51.80M |
| Short long term debt total | 19677.00M | 22176.00M | 21204.00M | 21729.10M | 9740.30M |
| Other stockholder equity | 12072.00M | 10090.00M | 9698.00M | 7564.60M | 5834.30M |
| Property plant equipment | 3956.00M | 3790.00M | 3262.00M | 2302.00M | 2511.20M |
| Total current assets | 15883.00M | 11648.00M | 13802.00M | 25596.60M | 7093.80M |
| Long term investments | - | - | - | 33.70M | 38.30M |
| Net tangible assets | -11638.00M | -22128.00M | -20204.00M | -3791.20M | -9364.70M |
| Net receivables | 4918.00M | 4631.00M | 4045.00M | 3191.40M | 3489.60M |
| Long term debt | 19086.00M | 22168.00M | 21193.00M | 21516.70M | 9688.50M |
| Inventory | 3110.00M | 2767.00M | 2292.00M | 1628.30M | 1910.10M |
| Accounts payable | 2296.00M | 2569.00M | 2049.00M | 1514.40M | 1712.80M |
| Noncontrolling interest in consolidated entity | 8.00M | 10.00M | 11.00M | 11.30M | 12.30M |
| Accumulated other comprehensive income | -2872.00M | -1027.00M | -368.00M | -3068.30M | -2791.10M |
| Common stock total equity | 9.00M | 9.00M | 9.00M | 8.40M | 8.20M |
| Preferred stock total equity | 1668.00M | 3268.00M | 3268.00M | 1599.60M | - |
| Retained earnings total equity | 39205.00M | 32827.00M | 27159.00M | 24166.30M | 25163.00M |
| Non currrent assets other | 4459.00M | 3719.00M | 2395.00M | 1720.80M | 648.40M |
| Non current assets total | 68467.00M | 71536.00M | 62359.00M | 36485.00M | 40738.70M |
| Capital lease obligations | 1062.00M | 1096.00M | 974.00M | 796.90M | - |
| Long term debt total | 19086.00M | 22168.00M | 21193.00M | 21516.70M | 9688.50M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2234.00M | -808.00M | -329.00M | -241.00M | -126.70M |
| Change to liabilities | 81.00M | 320.00M | 372.00M | 422.60M | 216.90M |
| Total cashflows from investing activities | -2234.00M | -12987.00M | -21239.00M | -1238.10M | -2949.40M |
| Net borrowings | -1688.00M | 2063.00M | -1926.00M | 13343.60M | -442.10M |
| Total cash from financing activities | -2570.00M | 1295.00M | 1006.00M | 16365.90M | -797.00M |
| Change to operating activities | -2.00M | 135.00M | 247.00M | 452.20M | 131.70M |
| Net income | 7209.00M | 6347.00M | 3646.00M | 2432.30M | 2650.90M |
| Change in cash | 3409.00M | -3449.00M | -13877.00M | 19124.50M | 157.70M |
| Begin period cash flow | 2586.00M | 6035.00M | 19912.00M | 787.80M | 630.30M |
| End period cash flow | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 788.00M |
| Total cash from operating activities | 8519.00M | 8358.00M | 6208.00M | 3951.60M | 4022.00M |
| Issuance of capital stock | 31.00M | 86.00M | 3550.00M | 3816.30M | 96.00M |
| Depreciation | 2222.00M | 2168.00M | 1775.00M | 1189.50M | 1307.70M |
| Other cashflows from investing activities | -1082.00M | 37.00M | -20119.00M | -361.60M | -2167.00M |
| Dividends paid | 818.00M | 742.00M | 615.00M | 750.70M | 433.00M |
| Change to inventory | -486.00M | -502.00M | -123.00M | -21.90M | -143.30M |
| Change to account receivables | -477.00M | -611.00M | -264.00M | -156.40M | -58.30M |
| Sale purchase of stock | 934.00M | 3249.00M | 5704.00M | 16514.20M | 411.80M |
| Other cashflows from financing activities | -1752.00M | -16.00M | -3.00M | -43.30M | -364.00M |
| Change to netincome | -223.00M | 415.00M | 243.00M | 37.80M | -41.60M |
| Capital expenditures | 1152.00M | 1294.00M | 791.00M | 635.50M | 584.00M |
| Change receivables | -477.00M | -611.00M | -264.00M | -156.40M | -58.30M |
| Cash flows other operating | 7402.00M | 6530.00M | 4205.00M | 2480.00M | 2740.60M |
| Exchange rate changes | - | - | - | 45.10M | -117.70M |
| Cash and cash equivalents changes | 3715.00M | -3334.00M | -14025.00M | 19124.50M | 157.50M |
| Change in working capital | -1519.00M | -658.00M | 605.00M | -123.20M | -90.10M |
| Stock based compensation | 336.00M | 218.00M | 187.00M | 158.80M | 151.40M |
| Other non cash items | 830.00M | 601.00M | 457.00M | 709.40M | 197.20M |
| Free cash flow | 7367.00M | 7064.00M | 5417.00M | 3316.10M | 3438.00M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DHR Danaher Corporation |
2.14 0.94% |
230.11 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| TMO Thermo Fisher Scientific Inc |
15.69 2.30% |
698.34 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.25 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.81 3.50% |
22.35 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
| NTRA Natera Inc |
8.45 2.23% |
387.37 | - | 5000.00 | 18.68 | 27.76 | 18.36 | -26.80 |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
2200 Pennsylvania Avenue, NW, Washington, DC, United States, 20037-1701
202 828 0850
79000
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven M. Rales | Co-Founder & Chairman | 1951 |
| Mr. Rainer M. Blair | Pres, CEO & Director | 1964 |
| Mr. Mitchell P. Rales | Co-Founder & Director | 1957 |
| Mr. Matthew R. McGrew | CFO & Exec. VP | 1972 |
| Ms. Angela S. Lalor | Part Time Advisor | 1965 |
| Mr. Joakim Weidemanis | Exec. VP | 1969 |
| Ms. Jennifer L. Honeycutt | Exec. VP | 1970 |
| Mr. Christopher M. Bouda | Chief Accounting Officer | NA |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Sr. VP & Chief Science Officer | 1964 |
| Mr. John Bedford | VP of Investor Relations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.